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Selection of patient reported outcomes
questions reflecting symptoms for patients
with metastatic melanoma receiving
immunotherapy
Lærke K. Tolstrup1,2,3* , Lars Bastholt1,3, Ann-Dorthe Zwisler1,2,3, Karin B. Dieperink1,2,3 and Helle Pappot4
Abstract
Context: Toxicity-monitoring plays an important role in all cancer treatment, however, early recognition is vital for
detecting and treating immune-related symptoms. Preparing a Patient Reported Outcomes tool and including
melanoma patients receiving immunotherapy in the reporting of symptoms, may optimize toxicity-monitoring.
Objectives: The objective of this study was to identify the symptoms and their equivalent questions to include from
the Patient-Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE) library for melanoma
patients, receiving immunotherapy and, further, to evaluate if all relevant symptoms are covered by this tool.
Methods: To establish the relevant symptoms, three measures were taken. First, a literature search was carried out in
three databases. Second, a chart audit was performed including medical records from melanoma patients receiving
immunotherapy. Finally, the product information for the relevant immunotherapies was studied.
Results: Ten articles were included as a result of the literature search. As for the chart audit, a total of 37
patients (48 treatments with immunotherapy) were included. Overall, the reported symptoms from the literature
review aligned with those identified in the chart audit. The examination of the product information supported the
findings from review and chart audit, revealing only one additional symptom. In total, 28 PRO-CTCAE symptoms were
selected comprising of 56 PRO-questions plus an additional question on blood in stool.
Conclusion: When preparing a Patient Reported Outcomes tool it is important that the preparatory work of selecting
questions is done properly. By going through the literature, performing a chart audit, and examining the product
information, the most important and relevant symptoms have been uncovered, facilitating the design of a PROquestionnaire,
based on PRO-CTCAE, that fits the patient population under investigation.
Keywords: Patient-reported outcomes, PRO-CTCAE, Item-selection, Symptomatic toxicity, Adverse events, Melanoma,
Immunotherapy
Introduction
The number of Danes who are diagnosed with malignant
melanoma have increased significantly during the last
50 years. Approximately 2200 new cases are reported
every year. Malignant melanoma is the most common
cancer form in the 15–34 year old and more than 400
persons are diagnosed with metastatic disease each year
[1]. This development aligns with the development
worldwide [2]. When metastatic, the majority of patients
are treated with immunotherapy, using checkpoint in-
hibitors either as monotherapy or in combination [3].
Survival has improved significantly with these new treat-
ment strategies. However, the adverse events (AEs) that
patients may experience can be severe and potentially
life-threatening [4–7]. Studies report that 16% of patients
treated with immunotherapy targeting PD-1 experience
CTC > = grade 3 AEs measured by the Common Criteria
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for Adverse Events (CTCAE). With immunotherapy
targeting CTLA-4, the number is 27%, and when the
drugs are combined, the frequency is 55% [6]. With all
cancer drugs, toxicity-monitoring plays an important
role, however, early recognition is vital for detecting
and treating immune-related AEs. If symptoms are dis-
covered early, relevant treatment can be initiated in
time, and major complications avoided [8].
CTCAE is widely used when it comes to toxicity-moni-
toring in oncological, clinical trials and in routine cancer
care. The CTCAE consists of 790 AEs and is divided into
three categories: laboratory-based events, physical exam-
ination findings and symptomatic adverse events [9]. Phy-
sicians perform a systematic evaluation using the CTCAE
to describe the severity of organ toxicity for patients re-
ceiving cancer therapy. In Denmark, a melanoma patient
who receives immunotherapy will be clinically evaluated
every third week prior to treatment. Consequently, there
is a risk that a symptom may go from mild to severe in
the time span. Moreover, evidence suggests that clinicians
may underestimate symptom onset and severity compared
to patient report [10]. It may be hypothesized that includ-
ing patients in the reporting of symptoms - and more fre-
quently [11] - can optimize symptom monitoring.
One way to increase patient involvement is to use pa-
tient reported outcomes (PROs). Applying a PRO-tool
which resembles the well-known CTCAE grading scale
seems advantageous. For this purpose, the National
Cancer Institute has developed a tool appropriate for
patient self-reporting. A total of 78 symptoms, approxi-
mately 10%, in the CTCAE guidelines have been found
appropriate for self-monitoring and now constitute what
has been labeled as the PRO-CTCAE [10, 12]. As each
adverse event is elicited using between one to three
questions on frequency, severity and interference with
daily activities, there are 124 individual questions repre-
senting the 78 symptoms. From this question library and
its attached form builder, it is possible for researchers
and oncologists to choose relevant symptoms and create
a questionnaire [13]. The PRO-CTCAE is translated and
validated in a Danish version [14], and a Danish feasibility
study has recently been carried out [15], demonstrating that
the tool is feasible in a prostate cancer population receiving
chemotherapy. However, no guidelines exist on how to
select the relevant PRO-items representing expected symp-
toms in different disease and treatment situations.
The advantages of using PROs in cancer treatment
and care are debated [16, 17]. Current data suggests that
physical symptoms are more likely to improve after PRO
interventions compared to quality of life (QoL), supportive
care needs or psychological symptoms [16]. More evidence
is needed, however, to determine if the implementation of
PROs in relation to, for example, symptom reporting is
worthwhile. So far, research involving PRO-CTCAE has
focused on toxicity monitoring associated with other cancer
therapies [10]. The tool has not been reported as used by
patients receiving immunotherapy. The pattern of symp-
toms with this treatment modality differs considerably from
the one patients experience when they receive chemother-
apy [8]. Thus, it is highly relevant to select the symptoms
that fit the toxicity-profile and provide and an unbiased
presentation when designing a PRO-tool for melanoma
patients receiving immunotherapy [18].
The objective of this study was to identify the symptoms
appropriate for patient self-reporting and their equivalent
PRO-questions to include from the PRO-CTCAE library
for melanoma patients receiving immunotherapy and, fur-
ther, to evaluate if all relevant symptoms can be covered
by the tool.
Material and methods
To establish the relevant symptoms to include in a subse-
quent randomized trial, a project group was formed. Be-
sides the project manager, the group consisted of two
physicians who were experts in handling immune-related
symptoms. Moreover, one had experience with selecting
relevant PRO-CTCAE-items. It was decided in advance
that due to the purpose of the study i.e. to identify symp-
toms appropriate for self-reporting, labatory based events
and physical examination findings would be excluded dur-
ing the selection process. Only symptomatic AEs that the
patients would meaningfully be able to report were to be
included.
Literature search
A literature search was performed in the three literature
databases Pubmed, Embase, and Cinahl in June 2016
using the Boolean logical operators AND/OR to com-
bine the search terms. A combination of keywords for
cancer, immunotherapy, adverse events and melanoma
was combined. Before doing the final search, the search
terms were monitored by an expert on literature
searches which resulted in minor changes. Articles were
included if the studies described were randomized clin-
ical trials that i) compared immunotherapy with chemo-
therapy or placebo, ii) compared immunotherapy in
different doses, iii) compared different immunotherapies,
or iv) compared immunotherapy with other cancer ther-
apies. Articles not written in English were excluded.
Articles were eligible if indexed between January 1, 1996
and June 22, 2016.
First, one reviewer screened the titles and abstracts to
eliminate all irrelevant references. Second, another re-
viewer took part in determining the references relevant
for full text review. Hereafter, both reviewers jointly de-
cided which articles should be included.
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Chart audit
In addition to the literature review, a chart audit was
performed to examine if the AEs found in the inter-
national literature were consistent with symptoms
melanoma patients treated with immunotherapy experi-
enced in daily practice. The chart audit was performed
at the Department of Oncology at Odense University
Hospital in the Region of Southern Denmark. Permis-
sion was granted from the head of department.
Thirty-seven medical records were examined with oral
and written informed consent from patients between
June and August 2016. No selection criteria was applied
and all melanoma patients treated with immunotherapy
were asked to participate. No patients refused, however,
due to administrative errors, a few patients were not re-
cruited. The patients included in the chart audit had re-
ceived either anti-PD-1 or anti-CTLA-4. The AEs
identified in the medical records were primarily found in
a prespecified toxicity-monitoring form build upon the
CTCAE grading scale v4 for physicians to register the
severity of AEs. In addition, the free text notes in the
medical records were included. If a health professional
had noted, for example, that a patient suffered from
taste changes, the term was translated into the CTCAE
term dysgeusia, making it possible to align all the pa-
tients´ AEs.
Product information
Finally, the product information from the European
Medicines Agency (EMA) for Yervoy (Ipilimumab),
Keytruda (Pembrolizumab) and Opdivo (Nivolumab)
[19] were studied to ensure that no adverse events had
been overlooked. If an AE was reported in one of the
EMA sources - and not already identified by the two
other data souces - it was included if it affected more
than 10% of the patients.
After the construction of the PRO-CTCAE question-
naire, the instrument was pilot-tested by four patients
and five healthcare professionals to ensure face validity.
Results
Literature search
Initial literature searches retrieved 3.165 titles from the
databases. After title and abstract screening and full text
screening had been performed, ten articles fulfilled the
inclusion criteria and were extracted (Fig. 1). The articles
were randomized, clinical trials including a total of 5.706
patients (Table 1). Thus, the number of trial participants
were judged sufficient to satisfy the trial objective of
identifying relevant AEs. Only two trials had a sample
size of less than 400 patients and were not multi-center
trials. The immunotherapy in the trials was either com-
pared to placebo, other immunotherapy, or other anti-can-
cer drugs. The studies tested Ipilimumab [4–6, 20, 21],
Pembrolizumab [7, 21, 22] or Nivolumab [6, 23, 24] as
monotherapy or a combination [6, 20] of two of the drugs.
One study [25] evaluated sequential single-drug therapy
with Ipilimumab followed by Nivolumab (or the reverse
sequence). One article evaluated Ipilimumab given as adju-
vant therapy, whereas the remaining nine were all con-
cerned with treatment of metastatic disease. Some of the
articles, including supplementary material, decribed the
most common AEs, occurring in at least 5–10% of patients,
while others also reported AEs that occurred in as few as
1–2% of the patients.
Chart audit
Among the 37 patients, 23 received Pembrolizumab,
three Ipilimumab and 11 received both immunother-
apies in sequence. All patients received at least one
dose of immunotherapy. In total, the 37 patients re-
ceived 48 treatments which were included in evaluation
of AEs. None of the patients received combination
immunotherapy.
Fig. 1 Article selection flowchart. Articles on immune-related adverse
events identified in melanoma patients treated with immunotherapy
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Product information
One additional AE, injection site reaction, was identified
as being very common from the European Medicines
Agency (EMA) product information on the three drugs.
The AE had also occurred in one of the articles, however,
since it was only identified in one data source and not
being very common, it had not been initially included.
Adverse events to be included in the PRO-CTCA for
melanoma patients
After thorough investigation of the literature, patients´ med-
ical records and the product information 28 AEs were iden-
tified as relevant to include from the PRO-CTCAE-library
(Table 2). Overall, there was great conformity between the
three data sources.
Fifteen AEs were very common (may affect at least
10% of the patients). Eight of these (nausea, anorexia,
diarrhea, abdominal pain, rash, pruritus, arthralgia,
fatigue) were found common in all three data sources.
The remaining seven (vomiting, constipation, dyspnea,
myalgia, injection site reaction, headache and chills)
were found very common in at least one or two of the
data sources. The AE asthenia was also very common in
both scientific papers and product information, however,
since it was not found in the CTCAE or the PRO-
CTCAE library, it was not included. This did not consti-
tute a problem since the symptom was covered by the
term fatigue which was found in the PRO-CTCAE-li-
brary. Fatigue is preferentially used in NCI’s toxicity
grading scale that covers fatigue, asthenia, and
malaise [26].
Eleven toxicities were found to be common (may
affect up to 10% of patients) in two or three of the three
data sources and were therefore included (Table 2).
Other AEs which were also common such as flu-like
symptoms, pain in extremity, and back pain were not
included since they were not items in the PRO-CTCAE
library. These terms seem adequately covered by muscle
pain, joint pain, chills and the more general AE pain and
thus, it was justifiable to exclude them.
Although the AE depression was uncommon [19] it
was included as it was the only symptom dealing with
mental health. Albeit rare, these symptoms can become
very severe. Accordingly, two items from the PRO-CTCAE
library concerning depression were selected. Despite the
fact that the toxicity blood in stool was neither present in
the PRO-CTCAE nor common, it was included as it may
be a sign of colitis, a severe immune-related AE [27]. The
question was placed at the end of the questionnaire as it
was not a PRO-CTCAE item.
At face value, the questionnaire appeared to be a good
instrument that adequately covered the relevant adverse
events. Moreover, filling it out seemed to be uncompli-
cated and quick.
Discussion
It was found that the AEs identified in the chart audit
were consistent with the ones found in the literature
search and the product information. This indicates that
the information collected from these three sources was
representative for melanoma patients receiving immuno-
therapy and usable when selecting relevant symptoms
Table 1 Characteristics of studies included to determine which AEs to include in the PRO-CTCAE for melanoma patients
Trial Design Enrollment size N= Study drug Dose (mg/kg)
Eggermont et al. [3] Adjuvant,
Randomized
phase 3
951 Ipilimumab 10
Hodi et al. [2] Phase 3
Randomized
676 Ipilimumab 3
Larkin et al. [4] Phase 3
randomized
945 Nivolumab
Nivolumab/Ipilimumab
Ipilimumab
3;
1 + 3;
3
Postow et al. [17] Double-blind
Phase 2 – dose ranging
142 Ipilimumab or
Ipilimumab/Nivolumab
3;
3 + 1
Ribas et al. [19] Phase 1b 655 Pembrolizumab
Pembrolizumab
10;
2
Ribas et al. [5] Phase 2 540 Pembrolizumab
Pembrolizumab
2;
10
Robert et al. [20] Randomized, phase 2 418 Nivolumab 3
Robert et al. [18] Phase 3 834 Pembrolizumab ipilimunab 10;
3
Weber et al. [21] Randomized, open-label phase 3 405 Nivolumab 3
Weber et al. [22] Randomized, open label, phase 2 140 Nivolumab
Ipilimumab
3;
3
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from the PRO-CTCAE library. The three information
sources provided a clear picture of which symptoms to
include in a questionnaire. Based on these findings, 28
PRO-CTCAE symptoms have been selected comprising
of 56 PRO-questions plus an additional question on
blood in stool.
It may be argued that having to leave a few symptoms out
because they are not present in the PRO-CTCAE-library is
a limitation. On the other hand, it is our belief that as long
as these items are adequately covered by other items, the
decision is justifiable. As the two PRO-CTCAE items deal-
ing with depression can become very severe and may be
hard to detect in a consultation at the outpatient clinic, it is
vital that they are discovered as they arise. Increased atten-
tion, for example through frequent patient reporting, may
be the way forward. When the study was designed, it was
discussed whether or not to carry out focus group interviews
with patients to further qualify the selection of items. We
decided against it due to the fact it would not be possible to
include all the experienced AEs anyway, however releveant
to the individual patient. The same experience has been
reported in other cancer poulations [28].
A special challenge in AE registration within immuno-
therapy may be that some symptoms occur rarely but
Table 2 Adverse events included in the PRO-CTCAE for melanoma patients receiving immunotherapy based on findings in medical
records, literature review and product information
Frequency of Adverse Events CTCAE terms Literature
review
Medical
records
Product
information
PRO-CTCAE symptom terms
Very common (may affect more than
1 in 10 people)
Vomiting X x Vomiting
Nausea x x x Nausea
Anorexia x x x Decreased appetite
Diarrhea x x x Diarrhea/Loose or watery stool
Abdominal pain x x x Abdominal pain
Constipation x x Constipation
Rash x x x Rash
Pruritus x x x Itching
Dyspnea x Shortness of breath
Myalgia x x Muscle pain
Arthralgia x x x Joint pain
Fatigue x x x Fatigue
Injection site reaction x Pain and swelling at injection site
Headache x x Headache
Chills x x Chills
̽
Asthenia x x
Common (may effect up to 1 in
10 people
Mucositis (oral) x x x Mouth/throat sores
Dry skin x x x Skin dryness
Alopecia x x Hair loss
Blurred vision x x x Blurred vision
Cough x x x Cough
Dysgeusia x x x Taste changes
Dizziness x x x Dizziness
Edema x x Swelling
Pain x x General pain
Peripheral sensory neuropathy x x Numbness & tingling
Hot Flashes x x Hot flashes
̽
Flu –like symptoms x x
̽
Pain in extremity x x
̽
Back pain x x
Uncommon/not present Depression (2 items) x Discouraged Sad
Blood in stool
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can be life-threatening if detected too late. This may be
an argument for including less frequent symptoms. On
the other hand, a subtle balance exists between including
the relevant symptoms while at the same time not
exhausting the patients with too many questions [29]. In
a previous study, it has been shown that a questionnaire
containing a similar number of PRO-CTCAE questions
(41 questions reflecting 22 symptomatic toxicities) has
proven feasible in a Danish prostate cancer population
receiving chemotherapy [15]. The patients found the
questionnaire easy to fill out and not too time consuming
(mean < 7min.). In addition, 40% reported that it in-
creased their focus on side effects. Others have demon-
strated similar results [12] which supports the clinical
feasibility of our suggested questionnaire for melanoma
patients. Moreover, the fact that patients have the oppor-
tunity of adding other symptoms decreases the risk of in-
frequent AEs not being reported. When designing the
study, it could have been considered to include a generic
questionnaire that also deals with patients´ health related
QoL such as the EORTC QLC-30 or the EQ-5D – used in
most melanoma studies [30]. However, the present study
focuses on detecting AEs early, and the PRO-CTCAE is
specifically developed to enable patients to report on ex-
perienced AEs. Based on findings from Basch et al. [31]
demonstrating improvement of QoL following PRO as
intervention future studies should be designed with the in-
clusion of Qol measurement.
Furthermore, the material included in our analysis
could be perceived as too comprehensive. Additional re-
search has been warranted, however, to qualify the selec-
tion ofPRO-CTCAE items for given populations and
contexts [32]. It was the purpose of this study to develop
a PRO-CTCAE questionnaire for use in patients with
metastatic melanoma who are treated with immunother-
apy in the future. Consequently, three of the ten articles
included described studies using the combination of two
immunotherapies. This treatment was not standard
treatment at the time of the review, however, it was
introduced in Denmark in 2017, justifying the inclusion
of studies testing the combination. Additionally, an
article dealing with Ipilimumab as adjuvant treatment
was included because the toxicity profile was evaluated
as being identical to the profile seen in metastatic dis-
ease. Thus, the questionnaire can also be used for mel-
anoma patients who receive adjuvant therapy.
Conclusion
When melanoma patients receive immunotherapy, close
monitoring of symptoms is crucial. One of the ways to
detect AEs early may be to have the patients self-report
the symptoms they experience, using PRO-questions. In
this regard, it is important that the preparatory work to
select questions is done properly. By going through the
literature, examining the product information, and per-
forming a chart audit, the most important and relevant
symptoms have been uncovered, making it possible to
design a PRO-questionnaire based on PRO-CTCAE that
fits the patient population under investigation. This
questionnaire is applied in an ongoing randomized clin-
ical trial (ClinicalTrials.gov. NCT03073031) where mel-
anoma patients treated with immunotherapy self-report
the symptoms they experience.
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